Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadalafil in BPH
NCT06466369Phase 3Completed
- Sponsor
- Al-Azhar University
- Start
- Mar 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tadalafil in benign prostatic hyperplasia (BPH) (3 arms), sponsored by Al-Azhar University. Primary endpoints: International Prostate Symptom Score at 3 months and International Index of Erectile Function at 3 months. Started Mar 2024; status: completed.
02
Drugs
tadalafil
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT06466369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06466369.